Gynecology Association Unfer Costabile, Obstetrics and Gynecology Center, Rome, Italy.
Gynecol Endocrinol. 2012 Jul;28(7):509-15. doi: 10.3109/09513590.2011.650660. Epub 2012 Feb 1.
Polycystic ovary syndrome (PCOS) affects 5%-10% of women in reproductive age, and it is the most common cause of infertility due to ovarian dysfunction and menstrual irregularity. Several studies have reported that insulin resistance is common in PCOS women, regardless of the body mass index. The importance of insulin resistance in PCOS is also suggested by the fact that insulin-sensitizing compounds have been proposed as putative treatments to solve the hyperinsulinemia-induced dysfunction of ovarian response to endogenous gonadotropins. Rescuing the ovarian response to endogenous gonadotropins reduces hyperandrogenemia and re-establishes menstrual cyclicity and ovulation, increasing the chance of a spontaneous pregnancy. Among the insulin-sensitizing compounds, there is myo-inosiol (MYO). Previous studies have demonstrated that MYO is capable of restoring spontaneous ovarian activity, and consequently fertility, in most patients with PCOS. With the present review, we aim to provide an overview on the clinical outcomes of the MYO use as a treatment to improve ovarian function and metabolic and hormonal parameters in women with PCOS.
多囊卵巢综合征（PCOS）影响了生育年龄的 5%-10%的女性，是由于卵巢功能障碍和月经不规律导致不孕的最常见原因。多项研究报告称，无论体重指数如何，胰岛素抵抗在 PCOS 女性中都很常见。胰岛素增敏化合物被提议作为潜在的治疗方法来解决内源性促性腺激素诱导的卵巢反应的高胰岛素血症，这也表明胰岛素抵抗在 PCOS 中的重要性。恢复内源性促性腺激素对卵巢的反应可降低高雄激素血症，并重新建立月经周期和排卵，增加自然妊娠的机会。在胰岛素增敏化合物中，有一种肌醇（MYO）。先前的研究表明，肌醇能够恢复大多数 PCOS 患者的自发性卵巢活动，从而恢复生育能力。通过本次综述，我们旨在概述肌醇作为治疗多囊卵巢综合征妇女改善卵巢功能和代谢及激素参数的临床效果。
